KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bio-Rad Laboratories (BIO) Buildings (2016 - 2022)

Bio-Rad Laboratories (BIO) has disclosed Buildings for 14 consecutive years, with $393.6 million as the latest value for Q4 2022.

  • On a quarterly basis, Buildings rose 2.03% to $393.6 million in Q4 2022 year-over-year; TTM through Dec 2022 was $393.6 million, a 2.03% increase, with the full-year FY2022 number at $393.6 million, up 2.03% from a year prior.
  • Buildings was $393.6 million for Q4 2022 at Bio-Rad Laboratories, up from $385.8 million in the prior quarter.
  • In the past five years, Buildings ranged from a high of $393.6 million in Q4 2022 to a low of $331.6 million in Q4 2018.
  • A 5-year average of $363.1 million and a median of $363.0 million in 2020 define the central range for Buildings.
  • Peak YoY movement for Buildings: rose 6.28% in 2020, then grew 2.03% in 2022.
  • Bio-Rad Laboratories' Buildings stood at $331.6 million in 2018, then rose by 3.03% to $341.6 million in 2019, then grew by 6.28% to $363.0 million in 2020, then rose by 6.27% to $385.8 million in 2021, then grew by 2.03% to $393.6 million in 2022.
  • Per Business Quant, the three most recent readings for BIO's Buildings are $393.6 million (Q4 2022), $385.8 million (Q4 2021), and $363.0 million (Q4 2020).